Long-term Safety, Efficacy of Bimekizumab in Chronic Plaque Psoriasis
Research type
Research Study
Full title
A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe Chronic Plaque Psioriasis
IRAS ID
249247
Contact name
Annika Harrison
Contact email
Sponsor organisation
UCB Biopharma SPRL
Eudract number
2016-003427-30
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
NAP, NAP
Duration of Study in the UK
2 years, 5 months, 0 days
Research summary
Research Summary:
Plaque Psoriasis is the most common form of Psoriasis, a long-term skin condition that appears as raised, red patches covered with a silvery white build-up of dead skin cells or scale. These patches or plaques most often appear on the scalp, knees, elbows and lower back. They are often itchy and painful, and they can crack and bleed.
The purpose of this study is to assess the long-term safety and tolerability of bimekizumab.
All participants receive the same drug (bimekizumab) and participants and study doctor will know what drug participants are receiving. Dosing of bimekizumab depends on participant's treatment plan in the preceding feeder study and the status of participant's psoriasis.
This study will take place worldwide and is sponsored by UCB Biopharma SPRL. It is anticipated that approximately 1120 participants will be enrolled in the study. For each participant, the study will last a maximum of 64 weeks.
Summary of Results:
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
18/NW/0721
Date of REC Opinion
31 Dec 2018
REC opinion
Further Information Favourable Opinion